Related Experiment Video
Updated: Jun 27, 2026

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
Published on: August 28, 2012
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis
James Signorovitch1, Jialu Zhang2, David Brown3
1Analysis Group, Boston, USA.
Developing multi-domain endpoints (MDEs) for immunoglobulin light chain (AL) amyloidosis is crucial for advancing new therapies. This initiative aims to create validated endpoints for clinical trials in this rare, multi-system disease.
Area of Science:
- Hematology
- Clinical Trials
- Drug Development
Background:
- Immunoglobulin light chain (AL) amyloidosis is a rare plasma cell disorder causing organ damage from amyloid fibril deposition.
- Therapeutic development for this heterogeneous disease necessitates standardized clinical trial endpoints.
Purpose of the Study:
- To propose a pathway for developing and validating multi-domain endpoints (MDEs) for AL amyloidosis clinical trials.
- To identify strategies for constructing MDEs using domain-specific endpoints across affected organs and life impacts.
Main Methods:
- A public-private partnership (Amyloidosis Research Consortium and FDA) formed the Amyloidosis Forum in 2020.
- The Statistical Group reviewed candidate endpoints from organ-specific working groups to explore MDE construction approaches.
Main Results:
- Considered various approaches for constructing MDEs by integrating domain-specific endpoints.
- Identified the need for future studies to validate MDEs using natural history and clinical trial data.
Conclusions:
- Validated MDEs are essential for advancing patient-focused drug development in AL amyloidosis.
- Endpoint selection should be guided by regulatory context, patient population, and therapeutic mechanism for drug development.
More Related Videos
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology